Zhou D J, Ahuja H, Cline M J
Department of Medicine, UCLA, 90024.
Oncogene. 1989 Jan;4(1):105-8.
The incidence of c-ERBB-2 amplification in breast cancers and its usefulness as a predictor of tumor recurrence after treatment have been subjects of controversy (Ali et al., 1988, Slamon et al., 1987). We re-examined this subject by analysing 157 primary and 14 metastatic breast cancers with c-ERBB-2 and 18 other molecular probes as controls. Five proto-oncogenes were found to be occasionally amplified in primary breast cancers: c-ERBB-2 (11%), c-MYB (3%), c-RAS-Ki (3%), INT-2 (4%) and c-MYC (6%). No statistically significant correlation between amplification of c-ERBB-2 and recurrence of tumors was observed. The only significant correlation observed was between early recurrence of advanced (stage III) tumors and amplification of one or another of the above five proto-oncogenes. We conclude that breast cancer utilize multiple genetic mechanisms in their progression and metastasis, and that analysis of c-ERBB-2 alone is not a useful guide.
乳腺癌中c-ERBB-2基因扩增的发生率及其作为治疗后肿瘤复发预测指标的实用性一直存在争议（Ali等人，1988年；Slamon等人，1987年）。我们通过分析157例原发性和14例转移性乳腺癌的c-ERBB-2基因以及另外18种分子探针作为对照，重新审视了这一问题。发现5种原癌基因在原发性乳腺癌中偶尔会发生扩增：c-ERBB-2（11%）、c-MYB（3%）、c-RAS-Ki（3%）、INT-2（4%）和c-MYC（6%）。未观察到c-ERBB-2基因扩增与肿瘤复发之间存在统计学上的显著相关性。观察到的唯一显著相关性是晚期（III期）肿瘤的早期复发与上述5种原癌基因中的一种或另一种基因的扩增之间的相关性。我们得出结论，乳腺癌在其进展和转移过程中利用多种遗传机制，仅分析c-ERBB-2基因并不是一个有用的指导。
